Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative Ketamine for Depression in Surgery
NCT03861988Phase 4Completed
- Sponsor
- Stanford University
- Start
- Aug 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ketamine in major depressive disorder (MDD) (3 arms), sponsored by Stanford University. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 3 days. Started Aug 2019; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03861988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861988.